To assess how a patient with pulmonary arterial hypertension (PAH) is faring on therapy, look at the right heart, said Anjali ...

Sotatercept-csrk reduced the risk of major morbidity and mortality events in adults with WHO Group 1 PAH FC 3 or 4 at high risk of mortality.

The PAH Initiative is hosting a video event in May to provide information about exercise benefits for PAH patients.

Keros Therapeutics halted phase 2 of TROPOS, but KER-065 shows promise in DMD and financial stability ensures growth ...

Late-breaking oral presentation to include full Phase 1b results for TX45 in the Group 2 Pulmonary Hypertension in Heart Failure with Preserved Ejection Fraction (“PH-HFpEF”) cohortWATERTOWN, Mass., ...

Treatments approved for PAH may reduce by half the risk of serious complications or death in patients with repaired ...

Bone morphogenetic protein receptor (BMPR)-II polymorphisms alone cannot account for the occurrence of PAH and a 'second-hit' is required. Serotonin can promote both pulmonary vasoconstriction and ...